5-hydroxytryptamine (5-HT) reduces total peripheral resistance during chronic infusion: Direct arterial mesenteric relaxation is not involved

BMC Pharmacology

Volumn 12, Issue , 2012, Pages

  Davis, Robert P ^a   Pattison, Jill ^a   Thompson, Janice M ^a   Tiniakov, Ruslan ^b   Scrogin, Karie E ^b   Watts, Stephanie W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Blood pressure; Hypotension; Serotonin (5 hydroxytryptamine, 5 HT)

Indexed keywords

1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; BW 723 C 86; DEOXYCORTICOSTERONE ACETATE; LP 44; MESSENGER RNA; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2B RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG INFUSION; HEART INDEX; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDIATOR; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE; SUPERIOR MESENTERIC ARTERY; VASCULAR RESISTANCE; VASODILATATION; WESTERN BLOTTING;

ANIMALS; BLOOD PRESSURE; DESOXYCORTICOSTERONE; ISOMETRIC CONTRACTION; MALE; MESENTERIC ARTERIES; MINERALOCORTICOIDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN RECEPTOR AGONISTS; VASCULAR RESISTANCE; VASODILATION;

EID: 84860499104     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-12-4     Document Type: Article

References (37)

1. Erspamer V, Aerso B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 1952, 169:800-801.
2. Dahlstroem A, Fuxe K. Evidence for the existence of monamine- containing neurons in the central nervous system. I. Demonstration of monamines in the cell bodies of brain stem neurons. Acta Physiol Scand 1964, 232(Suppl):1-55.
3. Watts SW, Davis RP. 5-Hydroxytryptamine Receptors in Systemic Hypertension: an arterial focus. Cardiovasc Ther 2010, 1:54-67.
4. Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin): IV isolation and characterization. J Biol Chem 1948, 176:1243-1251.
5. Yildiz O, Smith JR, Purdy RE. Serotonin and vasoconstrictor synergism. Life Sci 1998, 62(19):1723-1732. 10.1016/S0024-3205(97)01166-1, 9585103.
6. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 1999, 24(372):49-56.
7. Gul H, Yildiz O, Simsek A, Balkan, Ersoz N, Cetiner S, Isimer A, Sen D. Pharmacologic characterization of contractile serotonergic receptors in human isolated mesenteric artery. J Cardiovasc Pharmacol 2003, 41(2):307-315. 10.1097/00005344-200302000-00021, 12548093.
8. Bodelsson M, Tornebrandt K, Bertilsson IL, Arneklo-Nobin B. Heterogeneity of contractile 5-HT receptors in human hand veins. Eur J Pharmacol 1992, 219(3):455-460. 10.1016/0014-2999(92)90488-P, 1425972.
9. Cortijo J, Martí-Cabrera M, Bernabeu E, Domènech T, Bou J, Fernández AG, Beleta J, Palacios JM, Morcillo EJ. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br J Pharmacol 1997, 122:1455-1463. 10.1038/sj.bjp.0701509, 1565071, 9421295.
10. Brenner B, Harney JT, Ahmed BA, Jeffus BC, Unal R, Mehta JL, Kilic F. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem 2007, 102:206-215. 10.1111/j.1471-4159.2007.04542.x, 3041643, 17506858.
11. Fetkovska N, Pletscher A, Ferracin F, Amstein R, Buhler FR. Impaired uptake of 5-hydroxytryptamine in platelet in essential hypertension: clinical relevance. Cardiovasc Drugs Ther 1990, 4:105-109. 10.1007/BF00053439, 1704794.
12. Diaz J, Ni W, Thompson J, King A, Fink G, Watts SW. 5- hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats. J Pharmacol Exp Ther 2008, 325:1031-1038. 10.1124/jpet.108.136226, 18305011.
13. Borgdorff P, Fekkes D, Tangelder GJ. Hypotension caused by extracorpeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. Circulation 2002, 106:2588-2593. 10.1161/01.CIR.0000036082.04708.83, 12427656.
14. Calama F, Garcia M, Jarque MJ, Moran A, Martin ML, San Roman L. 5- hydroxytryptamine-induced vasodilator responses in the hindquarters of the anesthetized rat, involve beta2-adrenoreceptors. J Pharm Pharmacol 2003, 55(10):1371-1378.
15. Saxena PR, Villalon CM. Cardiovascular effects of serotonin agonists and antagonists. J Cardiovasc Pharmacol 1990, 15:S17-S34.
16. Delp MD, Manning RO, Bruckner JV, Armstrong RB. Distribution of cardiac output during diurnal changes of activity in rats. Am J Physiol 1991, 261:H1487-1493.
17. Tiniakov R, Osei-Owusu P, Scrogin K. The 5-Hydroxytryptamine1A receptor agonist, (+)-8-Hydroxy-2-(di-n-propylamino)-tetralin, increases cardiac output and renal perfusion in rats subjected to hypovolemic shock. JPET 2007, 320(2):811-818.
18. Ishida T, Kawashima S, Hirata K, Yokoyama M. Nitric Oxide is produced via 5-HT1B and 5-HT2B receptor activation in human coronary artery endothelial cells. Kobe J Med Sci 1998, 2:51-63.
19. Terron JA. Role of 5-HT7 receptors in the long-lasting hypotensive response induced by 5-hydroxytryptamine in the rat. Br J Pharmacol 1997, 121(3):563-571. 10.1038/sj.bjp.0701134, 1564697, 9179401.
20. De Vries P, De Visser PA, Heiligers JP, Villalon CM, Saxena PR. Changes in systemic and regional hemodynamics during 5-HT7 receptor-mediated depressor response in rats. Naunyn-Schmiedeberg's Arch Pharmacol 1999, 359(4):331-338.
21. Banes AK, Watts SW. Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension. BMC Pharmacol 2003, 3:1-15. 140036, 12513698.
22. Banes AK, Watts SW. Enhanced contraction to 5-hydroxytryptamine is not due to " unmasking" of 5-hydroxytrptamine(1b) receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat. Hypertension 2001, 38(4):891-895. 10.1161/hy1001.091779, 11641304.
23. Ellis ES, Byrne C, Murphy OE. Tilford NS and Baxter GS Mediation by 5- hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein. Br J Pharmacol 1995, 114:400-404. 10.1111/j.1476-5381.1995.tb13240.x, 1510266, 7881740.
24. Jähnichen S, Glusa E, Pertz HH. Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs. Naunyn-Schmied Arch Pharmacol 2005, 371(1):89-98.
25. Glusa E, Roos A. Endothelial 5-HT receptors mediate relaxation of porcine pulmonary arteries in response to ergotamine and dihydroergotamine. Br J Pharmacol 1994, 119:3303-3304.
26. Woodman OL, Dusting GJ. Involvement of nitric oxide in coronary vascular response to 5-hydroxytryptamine in the anaesthetized greyhound. Clin Exp Pharmacol Physiol 1994, 21:377-381. 10.1111/j.1440-1681.1994.tb02530.x, 7525131.
27. Haugen G, Mellembakken J, Stray-Pedersen. Characterization of the vasodilatatory response to serotonin in human umbilical arteries perfused in vitro. Influence of the endothelium. Early Hum Dev 1997, 47:185-193. 10.1016/S0378-3782(96)01778-1, 9039968.
28. Proctor DN, Parker BA. Vasodilation and vascular control in contracting muscle of the aging human. Microcirculation 2006, 13:315-327. 10.1080/10739680600618967, 16611597.
29. Kellogg DL, Zhao JL, Wu Y. Neuronal nitric oxide synthase control mechanisms in the cutaneous vasculature of humans in vivo. J Physiol 2008, 586(3):847-857. 2375621, 18048451.
30. Pacher P, Ungvari Z, Kecskemeti V, Koller A. Serotonin reuptake inhibitor, fluoxetine, dilates isolated skeletal muscle arterioles. Possible role of altered Ca2+ sensitivity. Br J Pharmacol 1999, 127(3):740-746. 10.1038/sj.bjp.0702571, 1566050, 10401565.
31. Alsip NL, Harris PD. Serotonin-induced dilatation of small arterioles is not mediated via endothelium-derived relaxing factor in skeletal muscle. Eur J Pharmacol 1992, 229:117-124. 10.1016/0014-2999(92)90544-E, 1490514.
32. Lin MT, Wu JJ, Tsay BL. Serotonergic mechanism in the hypothalamus mediated thermoregulatory responses in rats. Naunyn-Schmiedeberg's Arch Pharmacol 1983, 322:271-278.
33. Key BJ, Wigfield CC. Changes in tail surface temperature of the rat following injection of 5-hydroxytryptamine into the ventral medulla. Neuropharmacology 1992, 8:717-723.
34. Subramanian S, Vollmer RR. Fenfluramine-induced hypothermia is associated with cutaneous dilation in conscious rats. Pharmacol Biochem Behav 2004, 77(2):351-359. 10.1016/j.pbb.2003.11.009, 14751464.
35. Blauw G, Born AH, van Brummelen P, Camps J, Arndt JW, Verdouw PD, Chang PC, van Zwieten PA, Saxena PR. Effects of 5-hydroxytryptamine on capillary and arteriovenous anastomotic blood flow in the human hand and forearm and in the pig hind leg. J Cardiovasc Pharmacol 1991, 17(2):316-324. 10.1097/00005344-199102000-00019, 1709238.
36. Molderings GJ, Werner K, Likungu J, Göthert M. Inhibition of noradrenaline release from the sympathetic nerves of the human saphenous vein via presynaptic 5-HT receptors similar to the 5-HT 1D subtype. Naunyn Schmiedebergs Arch Pharmacol 1990, 324(4):371-377.
37. Nakatani Y, Sato-Suzuki I, Tsujino N, Nakasato A, Seki Y, Fumoto M, Arita H. Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat. Eur J Neurosci 2008, 29(9):2466-2472.